Skip to main content
. 2019 Jun 20;12(9):1185–1195. doi: 10.1016/j.tranon.2019.05.019

Figure 4.

Figure 4

Oncogenic capacity of FAM174A-WWC1. (A) SNV profiling of the enrolled EOCRC patients. The tumor expressing FAM174A-WWC1 had lowest number of oncogene mutations. (B) 3D spheroid forming assay indicated FAM174A-WWC1 expression significantly increased tumorsphere propagation.